« Return to News | R&D Trends

Chiromics, GSK enter into collaboration

Monday, November 19, 2012 12:09 PM

Chiromics, a drug discovery company, has formed a collaboration with global healthcare company GlaxoSmithKline to discover novel classes of small molecules against certain biological targets.

Chiromics' compound collections are assembled using Chiromics' core chemical technology referred to as "cascade catalysis." The technology was invented in the MacMillan Laboratories at Princeton University. Cascade catalysis allows for the creation of "accessible complexity"—a diverse collection of molecules that is more complex than and differentiated from currently existing small molecule collections, while retaining drug-like properties, the ability to develop structure-activity relationships and ease of re-synthesis.

The combination of Chiromics' chemical compound collection of accessible complexity, and Chalis, Chiromics' exclusive hit recognition algorithm for Affinity Screening, provides an opportunity for identification of new molecules that is complementary to conventional high throughput screening processes.

"We are pleased to enter into this collaboration with GSK. This collaboration further validates that our chemical technology and discovery platform is a potentially valuable gateway to a new set of small molecules for drug discovery,” said David MacMillan, Ph.D., founder of Chiromics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.